DTX-sHDL-CpG nanodisc administration into the tumor mass resulted in tumor regression and antitumor CD8+ T cell responses in the brain tumor microenvironment (TME), according to Kadiyala and her colleagues. This evidence concerns the gene CD8A and neoplasm.